What are Antifibrinolytic drugs?

Antifibrinolytic drugs are pharmacologic agents that share a common mechanism (typically targeting Plasminogen and plasmin). 1 are currently marketed, with 4 more in clinical development.

What are the marketed Antifibrinolytic drugs?

Marketed Antifibrinolytic drugs include ε-Aminocaproic Acid (EACA).

Antifibrinolytic

1 marketed 3 in Phase 3 1 in Phase 2

This page covers all Antifibrinolytic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Plasminogen and plasmin, Lysine receptor on plasminogen, Plasminogen activators and plasmin.

Targets

Plasminogen and plasmin · Lysine receptor on plasminogen · Plasminogen activators and plasmin

Marketed (1)

ε-Aminocaproic Acid (EACA) · Miller Orthopedic Specialists · Other

Phase 3 pipeline (3)

Topical application Tranexamic acid · Ain Shams University · Hematology
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby reducing fibrinolysis and improving hemostasis.
tranexamic acid (Exacyl®) · Institut Kassab d'Orthopédie · Oncology, Surgery
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots.
aprotinin or tranexamic acid · German Heart Center · Cardiovascular
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby reducing fibrinolysis and preventing excessive bleeding.

Phase 2 pipeline (1)

Antifibrinolytic treatment · Bayer · Oncology
Antifibrinolytic agents inhibit plasminogen activators and plasmin.